dc.date.accessioned | 2021-08-06T15:39:19Z | |
dc.date.available | 2021-08-06T15:39:19Z | |
dc.date.created | 2021-07-07T13:47:34Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Moum, Kristian Marling Moum, Bjørn Opheim, Randi . Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives’ on COVID-19 and health care service during the pandemic. Scandinavian Journal of Gastroenterology. 2021, 56(5), 1-8 | |
dc.identifier.uri | http://hdl.handle.net/10852/86694 | |
dc.description.abstract | Background and aims
Patients with inflammatory bowel diseases (IBD) have experienced changes to the routine management because of the SARS-CoV-2 pandemic. The aim of this study was to examine patients with IBD’s adherence to the restrictions imposed by society and the hospital, worries and concerns regarding medical treatment and clinical follow-up under the pandemic.
Methods
IBD patients (≥18 years) at the outpatient clinic at Oslo University Hospital were included and answered a self-report questionnaire including concerns regarding their disease, medical therapy and follow-up during SARS-CoV-2 pandemic.
Results
In total, 522 IBD patients were included, 317 Crohn’s disease, 205 ulcerative colitis, 386 patients <50 years. Eighteen percent were in obligatory quarantine, and more often patients <50 years compared to patients ≥50 years. Five patients tested positive to SARS- CoV-2. A higher proportion <50 years reported worries for their medical treatment and risk of COVID −19 disease compared to those ≥50 years. Forty percent avoided family, two-thirds avoided friends, and 4% cancelled their scheduled consultation at the hospital. The hospital changed physical consultation to telephone consultation for 15% of the patients. The preferred follow-up was physical consultation. A higher proportion of the patients <50 years preferred telephone consultation compared to those ≥50 years. Four out of five IBD patients were satisfied with the information about their IBD and COVID-19.
Conclusions
SARS-CoV-2 pandemic affects the daily lives for patients with IBD. It is important to develop evidence-base guidelines in follow-up and treatment, as well as patient information about COVID-19and IBD. | |
dc.language | EN | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives’ on COVID-19 and health care service during the pandemic | |
dc.type | Journal article | |
dc.creator.author | Moum, Kristian Marling | |
dc.creator.author | Moum, Bjørn | |
dc.creator.author | Opheim, Randi | |
cristin.unitcode | 185,53,11,13 | |
cristin.unitname | Gastromedisinsk avdeling | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1920723 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Scandinavian Journal of Gastroenterology&rft.volume=56&rft.spage=1&rft.date=2021 | |
dc.identifier.jtitle | Scandinavian Journal of Gastroenterology | |
dc.identifier.volume | 56 | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 545 | |
dc.identifier.endpage | 551 | |
dc.identifier.doi | https://doi.org/10.1080/00365521.2021.1901308 | |
dc.identifier.urn | URN:NBN:no-89331 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0036-5521 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/86694/1/Patients%2Bwith%2Binflammatory%2Bbowel%2Bdisease%2Bon%2Bimmunosuppressive%2Bdrugs%2Bperspectives%2Bon%2BCOVID%2B19%2Band%2Bhealth%2Bcare%2Bservice%2Bduring%2Bthe%2Bpandemic.pdf | |
dc.type.version | PublishedVersion | |